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Abstract
Background: Huntington's disease (HD) is an inherited neurogenerative disease caused by an
abnormal expansion of glutamine repeats in the huntingtin protein. There is currently no treatment
to prevent the neurodegeneration caused by this devastating disorder. Huntingtin has been shown
to be a positive regulator of vesicular transport, particularly for neurotrophins such as brain-
derived neurotrophic factor (BDNF). This function is lost in patients with HD, resulting in a
decrease in neurotrophic support and subsequent neuronal death. One promising line of treatment
is therefore the restoration of huntingtin function in BDNF transport.
Results: The phosphorylation of huntingtin at serine 421 (S421) restores its function in axonal
transport. We therefore investigated whether inhibition of calcineurin, the bona fide huntingtin
S421 phosphatase, restored the transport defects observed in HD. We found that pharmacological
inhibition of calcineurin by FK506 led to sustained phosphorylation of mutant huntingtin at S421.
FK506 restored BDNF transport in two complementary models: rat primary neuronal cultures
expressing mutant huntingtin and mouse cortical neurons from HdhQ111/Q111 HD knock-in mice.
This effect was the result of specific calcineurin inhibition, as calcineurin silencing restored both
anterograde and retrograde transport in neurons from HdhQ111/Q111 mice. We also observed a
specific increase in calcineurin activity in the brain of HdhQ111/Q111 mice potentially accounting for
the selective loss of huntingtin phosphorylation and contributing to neuronal cell death in HD.
Conclusion: Our results validate calcineurin as a target for the treatment of HD and provide the
first demonstration of the restoration of huntingtin function by an FDA-approved compound.
Background
An abnormal polyglutamine (polyQ) expansion in the N-
terminal part of the huntingtin protein causes Hunting-
ton's disease (HD), a fatal neurodegenerative disorder
characterized by the dysfunction and death of striatal and
cortical neurons in the brain [1]. HD is characterized by
motor, cognitive and psychiatric symptoms and the age at
onset is inversely correlated with the number of CAGs
encoding glutamines in the huntingtin protein. There is
currently no effective treatment for preventing the death
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of neurons in the brain or disease progression. Promising
treatment strategies involve the identification of com-
pounds capable of restoring functions altered in disease
[2].
The mechanisms underlying neuronal dysfunction and
death in HD are complex and involve both a gain of new
toxic functions and a loss of the neuroprotective functions
of wild-type huntingtin [1]. Several groups have demon-
strated changes in the microtubule (MT)-dependent trans-
port of vesicles, such as those containing brain-derived
neurotrophic factor (BDNF), in diseased neurons [3-7].
This trafficking defect is an early pathogenic event and is
linked to the association of huntingtin with components
of the molecular motor machinery [3,8-13] and its func-
tion as a direct regulator of MT-dependent transport in
different cell type including neurons [3,10,12].
Huntingtin phosphorylation at S421 abolishes the toxic-
ity of mutant huntingtin in vitro and in vivo [14,15]. We
recently demonstrated that the phosphorylation of
mutant huntingtin at the S421 residue promotes neuro-
protection in HD, by restoring huntingtin function in the
transport of BDNF [16]. In particular, we found that path-
ogenic polyQ-huntingtin with an S421 mutation mimick-
ing constitutive phosphorylation transports vesicles as
efficiently as the wild-type protein. However, the potential
benefits of drugs promoting huntingtin S421 phosphor-
ylation and abolishing the transport defect in HD remain
to be evaluated. Huntingtin phosphorylation at S421 is
induced by the IGF-1/Akt pathway and inhibited by cal-
cineurin [14,15]. Lower than normal levels of huntingtin
phosphorylation are found in various HD models
[15,17]. These lower levels of phosphorylation may be
due to changes in Akt during disease progression, as
observed in animal models and in the brains of HD
patients [14,18] and/or an increase in calcineurin activity
[15]. Consistent with this hypothesis, calcineurin levels
have been found to be higher than normal in neuronal
cells immortalized from HD mice [19]. A decrease in the
levels of RCAN1-1L, a negative regulator of calcineurin, in
the brains of HD patients may also account for the lower
levels of huntingtin phosphorylation observed [20]. These
observations suggest that calcineurin inhibition may be of
benefit in the treatment of HD.
Calcineurin is a serine-threonine phosphatase that is
highly abundant in neuronal tissues. It consists of a cal-
modulin-binding 60 kDa catalytic subunit, calcineurin A
(CaNA), and an intrinsic Ca+2-binding 19 kDa regulatory
subunit, calcineurin B (CaNB) [21-24]. The C-terminal
part of CaNA contains autoinhibitory and calmodulin-
binding domains and this subunit is regulated by various
endogenous regulators, including RCAN proteins [25-30].
Calcineurin is also efficiently blocked by FK506, an
immunosuppressive drug that must bind to FK506-bind-
ing proteins to exert its effects. FK506 has been shown to
be neuroprotective in various neurodegenerative para-
digms [31,32].
In this study, we investigated the potential value of cal-
cineurin as a target for the treatment of HD by pharmaco-
logical and silencing approaches. Calcineurin activity was
found to be dysregulated in the brains of HD mice. FK506
and siRNAs targeting calcineurin increased huntingtin
phosphorylation, restoring the capacity of this protein to
transport BDNF in neurons to levels similar to those in the
wild-type. Thus, drugs or pathways blocking calcineurin
activity are of potential interest for the treatment of HD.
Results
FK506 increases huntingtin phosphorylation at S421 in 
primary cortical neurons from HdhQ111/Q111 mice
Previous studies have demonstrated that calcineurin
dephosphorylates the S421 residue of huntingtin in rat
cultures in vitro and that calcineurin inhibition results in
an increase in huntingtin phosphorylation in transfected
cells [15]. As a first step towards validating calcineurin as
a treatment target, we investigated whether endogenous
mutant huntingtin could be phosphorylated in neurons.
We established primary cultures of neurons from HdhQ111/
Q111 embryos and analyzed the extent to which various
concentrations of FK506 induced the selective phosphor-
ylation of huntingtin at S421, using a highly specific
S421-phospho-htt antibody [15]. The treatment of pri-
mary neurons for one hour with FK506 at a concentration
of at least 0.3 μM induced a significant increase in the
selective phosphorylation of endogenous mutant hunt-
ingtin, as shown by Western blotting (Figure 1A). We
expressed huntingtin phosphorylation as the ratio of
phosphorylated to total huntingtin, using α-tubulin as a
loading control, and found that increasing FK506 concen-
tration induced progressive, strong phosphorylation at
S421. A significant increase in phosphorylation was
observed from concentrations as low as 0.1 μM (Figure
1B).
FK506 corrects the polyQ-huntingtin-induced defect in 
BDNF transport in rat cortical neurons
We previously demonstrated that a mutation mimicking
constitutive phosphorylation at S421 (a serine to aspartic
acid substitution) restored the capacity of transfected
mutant polyQ-huntingtin to transport BDNF at velocities
similar to those achieved by the wild-type protein [13].
We investigated whether FK506 could rescue the transport
defect induced by the polyQ expansion, by analyzing the
dynamics of BDNF-mCherry-containing vesicles in rat pri-
mary cultures by fast 3D videomicroscopy followed by
deconvolution, as previously described [3,12,13,33].
Video experiments were performed three days after the
electroporation of primary cultures of embryonic E17 rat
cortical neurons. We checked that the differences in trans-Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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port observed were due to the effect of the drug on the N-
ter fragment of huntingtin generated from the construct
used for transfection (either wild-type or mutant polyQ)
rather than the endogenous wild-type huntingtin present
in rat cortical neurons, by first decreasing endogenous
huntingtin levels by RNA interference with an siRNA tar-
geting the mouse huntingtin sequence (siRNA1) (Figure
2A). This "replacement" strategy has previously been used
to demonstrate that siRNAs targeting huntingtin have no
off-target effects and that the wild-type huntingtin N-ter-
minal fragment reproduces the transport function of the
full-length protein [13]. We found that the siRNA targeted
the endogenous mouse huntingtin specifically, with no
effect on the expression of the various transgenes (Figure
2B).
We then investigated the effects of the various constructs
on BDNF vesicular transport. As previously reported
[3,12,13,33], an N-terminal 480-amino acid fragment of
huntingtin with a wild-type glutamine stretch (480-17Q)
stimulated transport, whereas this function was lost if the
huntingtin contained the pathological expanded polyQ
stretch (Figure 2C-F). In particular, we observed signifi-
cant effects of the polyQ expansion on both antero- and
retrograde movement and on other dynamic parameters,
such as the percentage of pausing time (Figure 2E) and the
total distance traveled (Figure 2F). Our findings confirm
that the wild-type huntingtin fragment reproduces the
transport function of the full-length protein [13]. We next
investigated whether FK506 could correct the mutant
huntingtin-induced transport defect. Neurons were main-
tained in Neurobasal B27 serum-free medium to prevent
high basal levels of huntingtin phosphorylation at S421.
One hour of treatment with FK506 at a concentration
inducing maximal levels of huntingtin phosphorylation
(Figure 1A) restored dynamic parameters to control levels
(Figure 2C-F and Supplemental Movie 1). In particular,
FK506 significantly increased BDNF transport velocities in
480-68Q expressing neurons to 480-17Q levels, for both
anterograde values (480-17Q + DMSO: 0.41 ± 0.02 μm/s;
480-68Q + DMSO: 0.26 ± 0.02 μm/s; 480-68Q + FK506 1
μM: 0.45 ± 0.03 μm/s; Tukey HSD p < 0.0002)(Figure 2C)
and retrograde values (480-17Q + DMSO: 0.45 ± 0.07
μm/s; 480-68Q + DMSO: 0.27 ± 0.02 μm/s; 480-68Q +
FK506 1 μM: 0.45 ± 0.07 μm/s; Tukey HSD p < 0.0002)
(Figure 2D). FK506 treatment also significantly decreased
the pausing time of 480-68Q-electroporated neurons
(91.55 ± 6.87%) to a value (47.46 ± 4.84%) within the
range for 480-17Q electroporated neurons (44.18 ±
3.80%, Tukey HSD p < 0.0002) (Figure 2E). Strikingly, we
also observed a significant effect of FK506 on the total dis-
tance covered by vesicles (Figure 2F).
The addition of 1 μM FK506 to cells expressing wild-type
huntingtin did not significantly increase anterograde or
retrograde velocities, consistent with huntingtin being
highly phosphorylated in wild-type conditions, with no
further phosphorylation possible upon calcineurin inhi-
bition (Figure 2C-F). Thus, FK506 corrects the BDNF
transport defect in neurons expressing mutant huntingtin.
FK506 restores BDNF transport in cortical neurons from 
HdhQ111/Q111 mice
We tried to extend our findings to more physiological
conditions and to determine the minimal concentration
of FK506 required to rescue axonal transport, by culturing
cortical primary neurons from HdhQ111/Q111  mice and
FK506 increases huntingtin phosphorylation at S421 in pri- mary cultures of mouse HdhQ111/Q111 cortical neurons Figure 1
FK506 increases huntingtin phosphorylation at S421 
in primary cultures of mouse HdhQ111/Q111 cortical 
neurons. A) 3 DIV cortical primary neurons were treated 
with DMSO or different FK506 concentrations (0.1 μM, 0.3 
μM and 1 μM) for 1 hour and processed for Western blot-
ting analysis with anti-phospho-huntingtin-S421-714, anti-
huntingtin mAb4C8 or anti-α-tubulin antibodies. (B) Graph 
represents the quantitative assessment of the optical density 
of phosphorylated huntingtin on three independent experi-
ments and is expressed as the phospho-huntingtin/total hunt-
ingtin ratio normalised to total huntingtin. O.D. ratios, 
DMSO versus FK506 0.1 μM and 0.3 μM (**p < 0.01), FK506 
1 μM (**p < 0.001).Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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FK506 restores polyQ-induced alteration of BDNF-vesicular transport in rat cortical neurons Figure 2
FK506 restores polyQ-induced alteration of BDNF-vesicular transport in rat cortical neurons. A) Rat cortical 
neurons were electropored to silence endogenous huntingtin and samples were analyzed by Western blotting for huntingtin 
expression. (B) Immunostaining of electroporated cortical neurons silenced or not for endogenous huntingtin and ectopically 
expressing the first 480 amino acids of huntingtin containing 17Q repeats (480-17Q, normal) or 68Q repeats (480-68Q, 
mutant). Whereas huntingtin silencing depletes efficiently endogenous huntingtin in individual neurons, it does not impair the 
re-expression of the various huntingtin constructs nor the expression of BDNF-mCherry. (C and D) FK506 treatment at 1 μM 
concentration restores both anterograde and retrograde transport of BDNF vesicles to wild type values (anterograde ***p < 
0.0001 and retrograde ***p < 0.0001) but has no significant effect on the wild-type huntingtin fragment (anterograde velocity p 
= 0.10; NS and retrograde velocity p = 0.78; NS). (E) Pausing time altered in 480-68Q condition is reduced by FK506 treatment 
(***p < 0.0001) without having any effect in wild-type condition (p = 0.38; NS). (F) Total traveled distance of BDNF-Cherry 
tagged vesicles are significantly decreased in 480-68Q expressing neurons (***p < 0.001) and restored by FK506 treatment 
(***p < 0.001). Data are from three independent experiments: 6850 tracks, 24 neurons for 480-17Q with DMSO, 1383 tracks, 
8 neurons for 480-17Q with FK506 1 μM, 3934 tracks, 15 neurons for 480-68Q with DMSO, 4910 tracks, 19 cells for 480-
68Q with FK506 1 μM. Scale bar corresponds to 10 μm.Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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treating them with various concentrations of FK506.
FK506 concentrations as low as 0.1 μM were sufficient to
increase both anterograde and retrograde transport signif-
icantly (Figure 3A-B). Indeed, DMSO-treated neurons dis-
played transport velocities of about 0.25 ± 0.02 μm/s,
whereas neurons treated with 0.1 μM FK506 displayed
faster anterograde transport, at a velocity of 0.37 ± 0.04
μm/s (p < 0.006), and retrograde transport, at a velocity of
0.40 ± 0.04 μm/s (p < 0.0005). FK506 also significantly
reduced the pausing time (Figure 3C). FK506 treatment
significantly increased the dynamics of BDNF-containing
vesicles in HdhQ111/Q111 neurons as shown on representa-
tive movies (Supplemental Movie 2) and the correspond-
ing kymographs (Figure 3D). Interestingly, the values
obtained after treatment were similar to those for neurons
from wild-type animals (Supplemental Figure 1). Further-
more, we observed no significant difference in transport
velocity between the three concentrations (Figure 3A-B),
suggesting levels of huntingtin phosphorylation suffi-
ciently high to restore transport were achieved at a con-
centration of 0.1 μM. Finally, as previously reported for
electroporated rat neurons (Figure 2), FK506 had no effect
in wild-type conditions (Supplemental Figure 1). Thus,
pharmacological treatment with FK506 corrects the trans-
port defect in HD cortical neurons.
FK506 inhibits calcineurin activity in cortical neurons from 
HdhQ111/Q111 mice
We then investigated whether FK506 treatment, which
induced a significant increase in huntingtin phosphoryla-
tion and corrected the axonal transport defect due to
mutant huntingtin, led to calcineurin inhibition. We cul-
tured cortical primary neurons from HdhQ111/Q111 mice
and treated them with various concentrations of FK506
(0.1-1 μM). After 1 h of incubation with FK506 or DMSO,
the cells were lysed, ultracentrifuged and processed for the
detection of calcineurin activity (Figure 4). Calcineurin
was significantly inhibited at concentrations as low as 0.1
μM, a concentration inducing significant levels of hunt-
ingtin S421 phosphorylation and the recovery of axonal
transport. Together with our previous results, this indi-
cates that pharmacological inhibition of calcineurin by
FK506 induces polyQ-huntingtin phosphorylation and
the restoration of vesicular transport.
Genetic inhibition of calcineurin restores BDNF transport 
in cortical neurons from HdhQ111/Q111 mice
For the unequivocal demonstration that calcineurin is a
bona fide target for restoring BDNF transport, we tried to
inactivate calcineurin selectively by RNA interference
approaches. We electroporated primary cultures of corti-
cal neurons from HdhQ111/Q111 mice with an siRNA target-
ing the α and β isoforms of calcineurin. We previously
demonstrated that the targeting of both isoforms was
required to achieve significant silencing of calcineurin in
cortical neurons from wild-type mice [15]. Calcineurin
silencing in neurons from HdhQ111/Q111 mice was maximal
48 h after electroporation. This time peak in calcineurin
silencing coincided with a significant increase in hunting-
tin phosphorylation at S421 (Figure 5A). We used
p150Glued, a subunit of dynactin, as a loading control. We
then analyzed the dynamic parameters of BDNF vesicle
transport in HdhQ111/Q111 cortical neurons depleted of cal-
cineurin. We observed a significant increase in BDNF
dynamics, as shown by the increase in anterograde trans-
port (compare scramble RNA: 0.23 ± 0.01 μm/s with cal-
cineurin αβ siRNA: 0.33 ± 0.03 μm/s) (Figure 5B) and in
retrograde transport (compare scramble RNA: 0.23 ± 0.01
μm/s with calcineurin αβ siRNA: 0.33 ± 0.02 μm/s) (Fig-
ure 5C). The pausing time of BDNF vesicles was also sig-
nificantly shorter in HdhQ111/Q111  neurons in which
calcineurin was silenced (Figure 5D). The scramble RNA
had no effect on vesicular velocity in wild-type and
mutant condition, as shown by comparison with DMSO
treatment (compare Figure 3, Figure 5 and Supplemental
Figure 1). Finally, the dynamic parameters of transport in
HdhQ111/Q111 neurons silenced for calcineurin were found
to be similar to those in neurons from Hdh+/+ mice treated
with scramble RNA (anterograde velocity: 0.32 ± 0.03
μm/s and retrograde velocity: 0.34 ± 0.04 μm/s), consist-
ent with the full rescue of transport to wild-type levels.
Our findings demonstrate that calcineurin inhibition,
whether by genetic methods or pharmacological methods
based on FK506, restores the transport of BDNF vesicles,
which is defective in HD, and therefore, is of therapeutic
interest.
HD mice display high levels of calcineurin activity
We previously reported that huntingtin is phosphorylated
by Akt and that Akt is altered in post mortem brain samples
from HD patients [14] and during disease progression
[18]. This suggested that defects in Akt signaling pathway
might be involved in the low level of huntingtin phospho-
rylation observed in HD [15,17]. In addition, this low
level of phosphorylation may also be due to the dysregu-
lation of calcineurin in HD [15]. Calcineurin is very abun-
dant in brain, accounting for about 1% all the proteins
present in this organ [34]. We investigated calcineurin lev-
els in HD, by analyzing three regions of the brain -- the
striatum, cortex and subtantia nigra -- based on the rele-
vance of these regions to striatal afferences, BDNF trans-
port and degeneration. The striatum is the region most
affected in HD, and previous studies in cells of striatal ori-
gin have reported calcineurin dysregulation [19]. The cor-
tex is the major source of BDNF for the striatum, via the
cortico-striatal projections [35,36] and these neurons also
degenerate in HD [37]. We also analyzed the substantia
nigra, as neurons from this region project onto the stria-
tum via the nigrostriatal pathway, which is also defective
in HD, although this region is only a minor supplier ofMolecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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BDNF to striatal neurons [7,38,39]. Dissections were car-
ried out on one-year old mice, as HdhQ111/Q111 mice man-
ifest neurological symptoms at this time point [40].
Surprisingly, western blot analyses showed no difference
between Hdh+/+ and HdhQ111/Q111 mice in terms of the lev-
els of calcineurin A catalytic subunit in these three regions
(Figure 6A). As the cortex contains large amounts of cal-
cineurin and is the major supplier of BDNF to the stria-
tum, we determined the calcineurin activity in the cortex,
as described above (Figure 4). We found that calcineurin
accounted for 21 ± 8.31% of total phosphatase activity in
Hdh+/+ mouse cortex (Figure 6B). Surprisingly, levels of
calcineurin activity were found to be significantly higher
in HdhQ111/Q111 and HdhQ111/+ mice, at 49.85 ± 10.14%
(Figure 6B). Thus, higher levels of calcineurin activity are
observed in the brain during HD, suggesting that cal-
cineurin dysregulation may contribute to HD pathogene-
sis by decreasing huntingtin phosphorylation at S421.
Discussion
We demonstrate here that calcineurin is dysregulated in
Huntington's disease and that the pharmacological and
genetic inactivation of calcineurin leads to an increase in
the phosphorylation of mutant huntingtin at S421, result-
ing in the restoration of its function in the intracellular
transport of BDNF within cortical neurons.
Our results provide the first demonstration of a direct role
of calcineurin in the regulation of vesicular transport.
Huntingtin regulates the MT-dependent transport of
organelles in neurons [3,10,12,33] and this function is
regulated by phosphorylation in both physiological and
pathological conditions [12,13]. We found that muta-
tions mimicking huntingtin phosphorylation restored the
ability of mutated huntingtin to transport BDNF. Also, we
found that promoting huntingtin phosphorylation by
activating the IGF-1/Akt pathway, leading to huntingtin
phosphorylation at S421, restored the function of the
mutant huntingtin protein in MT-dependent transport
[13]. Our results demonstrating that calcineurin inhibi-
tion increases S421 phosphorylation and transport also
provide support for the notion that huntingtin phospho-
rylation at S421 is critical for regulation of the function of
this protein in transport and for neuronal death in HD
[12,13]. Consistent with these data, FK506 exerts neuro-
protective effects in neurons expressing polyQ-huntingtin
[15]. Our observation that calcineurin inhibition restores
BDNF trafficking and supply in the striatum in HD is con-
sistent with previous studies showing that calcineurin
inhibitors, such as cyclosporin A and FK506, decrease the
level of neuronal cell death in the hippocampus after fore-
brain ischemia in animal models [41,42]. BDNF was
reported to mediate the neuroprotective effect of cal-
cineurin inhibitors, as shown by the selective induction of
BDNF in the hippocampus of cyclosporine treated ani-
mals [43]. The induction of BDNF was linked to the
increase in pCREB levels and BDNF transcription, but our
results suggest that calcineurin inhibition could also
increase BDNF trophic support by stimulating the trans-
port of vesicles containing BDNF. Our results indicate that
further studies of the general role of calcineurin in the
control of intracellular trafficking in health and disease
are warranted.
FK506 restores transport alteration of BDNF-containing ves- icles in cortical HdhQ111/Q111 mice neurons Figure 3
FK506 restores transport alteration of BDNF-con-
taining vesicles in cortical HdhQ111/Q111 mice neurons. 
(A and B) Cortical primary neurons from knock-in Hunting-
ton's disease mice model were electropored with BDNF-
mCherry and incubated for 72 h. 1 h prior videomicroscopy 
experiment, neurons were treated with either DMSO or the 
following increasing concentrations of FK506 0.1 μM, 0.3 μM 
1 μM or DMSO. FK506 induced a statistically significant 
increase in both anterograde and retrograde velocities with 
all the tested concentrations (Anterograde: **p < 0.01 for 
0.1 μM, *p < 0.05 for 0.3 μM **p < 0.01 for 1 μM. Retro-
grade: ***p < 0.001 for 0.1 μM, *p < 0.05 for 0.3 μM **p < 
0.01 for 1 μM). No significant differences were observed 
between the different concentrations. (C) FK506 treatment 
also reduced significantly the pausing time of BDNF-mCherry 
vesicles observed in HdhQ111/Q111 mice cortical neurons (**p 
< 0.01 for 0.1 μM, 0.3 μM and 1 μM FK506 concentrations). 
Data are from two independent experiments, 3736 tracks, 8 
cells for HdhQ111/Q111 + DMSO, 4302 tracks, 10 cells for 
HdhQ111/Q111 + FK506 0.1 μM, 2959 tracks, 11 cells for 
HdhQ111/Q111 + FK506 0.3 μM, 2964 tracks, 8 cells for 
HdhQ111/Q111 + FK506 1 μM. (D) Representative kymographs 
of BDNF-mCherry dynamics in cortical neurons from 
HdhQ111/Q111mice treated with DMSO (upper kymograph) or 
1 μM FK506 during 30 min (lower kymograph).Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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Our results validate calcineurin as a target for treatment in
HD. We have demonstrated a specific change in cal-
cineurin activity in disease conditions. Indeed, although
calcineurin protein levels are similar in mouse brains con-
taining the wild-type and mutant HD, significantly higher
levels of calcineurin activity were observed in the cortex of
mutant mice. This dysregulation is consistent with the
downregulation of RCAN1-1L, a negative regulator of cal-
cineurin in brains affected by HD [20] and the distur-
bance of calcium concentrations in HD [44]. In addition,
activation of calcineurin could be induced by the cleavage
of its specific inhibitor cain/cabin1 following the activa-
tion of the protease calpain [45]. Indeed, calpain activity
is increased in HD brains and contributes to HD pathol-
ogy [46,47]. Further evidence for the specific dysregula-
tion of calcineurin in HD is provided by our observation
that the treatment of neurons expressing wild-type hunt-
ingtin with FK506 had no effect on vesicular transport,
whereas this treatment had a strong effect in neurons
expressing the mutant protein. We have also shown that
calcineurin activity is strongly inhibited by FK506 in neu-
rons from HD mice. Thus, drugs aiming to block cal-
cineurin activity are likely to be effective at treating the
disease. Finally, the inhibition of calcineurin through two
approaches, pharmacological and genetic in nature,
resulted in similar beneficial effects, with an increase in
the levels of phosphorylated huntingtin and correction of
the axonal transport defect observed in HD.
Conclusion
This study sheds light on the molecular mechanism by
which calcineurin inhibition blocks neuronal death in
HD. Our results extend the therapeutic potential of cal-
cineurin inhibitors such as FK506, an FDA-approved drug
capable of crossing the blood-brain barrier, and provide
evidence in favour of clinical trials of the use of such com-
pounds in HD patients.
Methods
Statistical analyses
Statview 4.5 software (SAS Institute Inc., Cary, NC) was
used for statistical analysis. Data are expressed as mean +/
- S.E.M.
Constructs and siRNA
The plasmid encoding BDNF-mCherry was a generous gift
from G. Banker (Oregon Health and Science University,
Portland, Oregon). BDNF-mCherry shows cellular locali-
zation, processing, and secretion properties indistinguish-
able from those of endogenous BDNF. The wild-type and
polyQ huntingtin constructs 480-17Q, 480-68Q, have
been previously described [48] and correspond to human-
mouse hybrids derived from mouse huntingtin cDNA:
first exon of mouse huntingtin has been substituted by the
homologous human one in mouse full length cDNA [49].
The siRNAs targeting mouse huntingtin correspond to the
coding region 361-380 (siRNA1) of huntingtin mouse
mRNA (GenBank Acc. n° XM_132009). The siRNA
sequences targeting rat CaNAα and CaNAβ correspond to
the coding regions 677-695 (GenBank Acc. No. NM
017041) and 448-466 (GenBank Acc. No. NM 017042)
respectively. The scramble RNA (scRNA) control (Euro-
gentec, Seraing, Belgium) used has a unique sequence
which does not match to any sequence in the genome of
interest.
Animals
Except for the experiments assessing BDNF transport in rat
cortical neurons, all the videomicroscopy experiments
and the biochemical analyses were conducted using
HdhQ111/+  HdhQ111/Q111  and the corresponding Hdh+/+
mice in the CD1 background. HdhQ111 knock-in mice, a
FK506 potently inhibits calcineurin activity in HdhQ111/Q111  neurons Figure 4
FK506 potently inhibits calcineurin activity in 
HdhQ111/Q111 neurons. Cortical primary cultures of neu-
rons from knock-in Huntington's disease mice were plated 
with B27 media for 72 h and next treated with various con-
centrations of FK506, 1 μM, 0.3 μM or 0.1 μM. After 1 h of 
incubation cells were lysed and processed to determine cal-
cineurin activity. Results show a significant reduction in cal-
cineurin activity in HD neurons for all tested concentration 
with no significant differences between concentrations. 
Results were expressed as percentage of calcineurin activity 
per gram of tissue. (**p < 0.01 for 1 μM, *p < 0.05 for 0.3 μM 
and 0.1 μM FK506 concentrations).Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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generous gift from M.E. MacDonald, have been previously
described [50]. For neuronal cultures from rat embryos,
time pregnant Sprague-Dawley rats were obtained from
Charles River Laboratories (Les Oncins, France). For
experiments requiring brain dissection (Western blotting
analyses and calcineurin assays), mice were deeply anaes-
thetized in a CO2 chamber, and their cortices, substantia
nigra and striata were dissected out on ice and rapidly fro-
zen using CO2 pellets. All experimental procedures were
performed in strict accordance with the recommendations
of the European Community (86/609/EEC) and the
French National Committee (87/848) for care and use of
laboratory animals.
Neuronal cultures and transfection
Primary cortical neurons from E17 rat or from HdhQ111/
Q111 or Hdh+/+ mouse E15 embryos were prepared, cul-
tured in Neurobasal B27 and transfected as described
[3,14,48]. Cortical neurons were electroporated with the
rat neuron Nucleofector® kit according to the supplier's
manual (Amaxa, Biosystem, Köln, Germany). For hunt-
ingtin gene replacement strategy, neurons were co-electro-
porated with siRNA1 and the 480-17Q or 480-68Q
plasmids. For FK506 treatment, cells were treated with
FK506 (0.1, 0.3, 1 μM; Alexis, Lausen, Switzerland) or
vehicle (DMSO) for 30 min before videomicroscopy. All
the experiments and in particular the videoexperiments
were conducted in conditions in which no overt toxicity
of the various constructs nor aggregation could be
detected. The co-expression of BDNF and the various con-
structs as well as RNAi efficiency was verified by immu-
nostaining after the videomicroscopy experiments. 95%
or more of co-expression was observed. Single cell analy-
sis of immunostaining levels revealed no difference in
huntingtin expression between the different constructs
nor signs of apoptosis in the conditions used.
Videomicroscopy experiments and imaging treatment
Videomicroscopy experiments were done 2-3 days after
transfection. Cells were cotransfected with BDNF-
mCherry and various constructs of huntingtin or the cor-
responding empty vectors with a DNA ratio of 1:4. Live
videomicroscopy was carried out using a Leica DM IRBE
microscope and a PL APO oil 100× objective with a
numerical aperture of 1.40-0.70, coupled to a piezo device
(PI) and recorded with Photometrics CoolSNAP HQ2
camera (Roper Scientific, Trenton, NJ) controlled by Met-
amorph software (Molecular Devices, Sunnyvale, CA).
Stacks were acquired in cultured medium at 37°C for cor-
tical neurons. Images were collected in stream set at 2 × 2
binning with an exposure time of 100 ms (frequency of
2s) with a Z-step of 300 nm. All stacks were treated by
automatic batch deconvolution using the PSF of the opti-
cal system, Meinel algorithm with parameters set at 7 iter-
ations, 0.7 sigma and 4 frequency. Maximal z and time
projection, animations and analyses of vesicles tracking
were done with ImageJ software as previously described
[33]. Supplemental movies and kymographs were
obtained by collecting images at a frequency of 1 image/s
with an acquisition time of 300 ms. The kymostacks were
generated using a homemade ImageJ KymoToolbox
plugin http://rsb.info.nih.gov/ij/, NIH, USA; available on
request at Fabrice.Cordelieres@curie.fr). For image analy-
ses of fixed samples, images were acquired at room tem-
perature with a Leica DM RXA microscope with a PL APO
oil 100× NA of 1.4 objective coupled to a piezo device (PI)
and a Micromax RTE/CCD-1300-Y/HS camera controlled
by Metamorph software. The mounting medium was 0.1
g/ml Mowiol 4-88 (Calbiochem, Merck Biosciences,
Darmstadt, Germany) in 20% glycerol. Z-stack was of 200
nm. Deconvolution was performed as for videomicros-
copy.
Silencing of calcineurin by RNA interference in cortical neu- rons from HdhQ111/Q111 mutant mice restores BDNF trans- port Figure 5
Silencing of calcineurin by RNA interference in corti-
cal neurons from HdhQ111/Q111 mutant mice restores 
BDNF transport. A) Cortical primary HD neurons were 
electroporated with BDNF-mCherry plasmid and siRNAs 
against the isoforms α and β of the calcineurin A subunit. 48 
h after electroporation, half of the neurons were lysed and 
extracts were analyzed by western blot for siRNA efficiency 
and huntingtin phosphorylation and, the other half of neu-
rons were analyzed by videomicroscopy (B-D). (B and C) 
Calcineurin depletion increase significantly anterograde (**p 
< 0.01) and retrograde (**p < 0.01) velocity of BDNF vesi-
cles. (D) Pausing time was reduced (**p < 0.01) in this 
mutant mice. Data are from two independent experiments, 
5550 tracks, 20 cells for scramble RNA and 3461 tracks, 16 
cells for siRNA calcineurin in HdhQ111/Q111 neurons.Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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Western blot analysis
For neuronal cultures, neurons were washed with ice-cold
PBS before scraping and lysis. In the case of experiments
assessing the efficient silencing of huntingtin or cal-
cineurin, half of the coverslips were lysed after videomi-
croscopy. For analyses of calcineurin in different brain
regions, dissected frozen samples were directly resus-
pended in lysis buffer. Composition of buffers and all the
procedures were performed as previously described [15].
6% and 10% acrylamide gels were respectively used for
huntingtin and calcineurin detection. 8% acrylamide gels
were used to detect the two proteins on the same blot.
Membranes were blocked in 5%BSA/TBST buffer (20 mM
Tris-HCl, 0.15 M NaCl, 0.1% Tween 20) and immunob-
lotted with anti-CaN Pan A (1:1000; Chemicon) or anti-
α-tubulin (1:10000; DM1A; Sigma, St Louis, MO),
p150Glued (clone 1, BD Biosciences, San Jose, CA, USA),
home made anti-phospho-htt-S421-714 [15] and anti-
huntingtin antibody mAb 4C8 (1:5000; clone 1HU-4C8,
[49]) antibodies for 1 h. Membranes were then labelled
with secondary IgG/HRP antibodies (Jackson ImmunoRe-
search, WestGrove, PA, USA), washed and incubated for 2
min with SuperSignalWest Pico Chemiluminescent Sub-
strate (Pierce, Erembodegem, Belgium) according to the
instructions of the supplier. Membranes were exposed to
Kodak (Rochester, NY) BioMax films and then developed.
Quantification of the signal was performed by densito-
metric scanning of the film using GelPRO analyzer soft-
ware.
Immunofluorescence
To ensure efficient silencing in electroporated neurons
used for videomicroscopy, coverslips were fixed after vid-
eorecording with methanol for 3 min, blocked 1 h in PBS
1% BSA and incubated with mAb 4C8 anti-huntingtin
antibody (1:100; [49]) during 90 min. Coverslips were
rinsed three times in PBS 1:1000 tween 20 and incubated
with a secondary Alexa 488 fluorescent antibody (Invitro-
gen, Oregon, USA). After incubation with DAPI (1:10000
in PBS; Roche, Indianapolis, USA), coverslips were rinsed
three times and mounted with Mowiol.
Calcineurin activity
Calcineurin activity was measured in primary cultures of
cortical neurons from HdhQ111/Q111 mice, and in samples
obtained from the cortex of 1 year old wild-type Hdh+/+
and mutant HdhQ111/Q111 and HdhQ111/+ mice using the
Calcineurin Cellular Activity Assay Kit (Calbiochem, San
Diego, CA, USA). For experiments on cultures, neurons
were treated with FK506 or DMSO and then lyzed in the
buffer supplied by the manufacturer. For cortex analyzes,
samples obtained from brain dissection were homoge-
neized in the supplied buffer. For both experiments, sam-
ples were processed according to the protocol provided by
the manufacturer. Calcineurin activity was determined as
the difference between total phosphatase activities minus
the phosphatase activity in presence of 10 mM EGTA that
blocks calcineurin activity. Data were expressed as the per-
centage of the total phosphatase activity.
Abbreviations
The abbreviations used are DIV: days in vitro; BDNF:
brain-derived neurotrophic factor; HD: Huntington's dis-
ease; MT: microtubule; O.D.: optical density; polyQ: pol-
yglutamine; S421: serine 421.
Calcineurin activity but not protein levels are increased in  HdhQ111/Q111 mouse brains Figure 6
Calcineurin activity but not protein levels are 
increased in HdhQ111/Q111 mouse brains. A) Calcineurin 
levels were analyzed in cortex, striatum and substantia nigra 
from HdhQ111/Q111 and Hdh+/+ mouse brains. No differences 
in protein levels were detected between wild type and HD 
condition. Note that calcineurin levels are lower in substantia 
nigra compared to cortex and striatum. (B) Calcineurin activ-
ity is significantly increased in the cortex of HdhQ111/Q111 and 
HdhQ111/+ mice compared to Hdh+/+ mice. Data are from 6 
mice per condition and were expressed as percentage of cal-
cineurin activity per gram of tissue. (***p < 0.001 for 
HdhQ111/+ and HdhQ111/Q111). No differences were found 
between HdhQ111/+ and HdhQ111/Q111 (p = 0.99; NS).Molecular Brain 2009, 2:33 http://www.molecularbrain.com/content/2/1/33
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